|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1,695.55 INR | -2.51% |
|
+3.17% | +6.51% |
| 11/03 | Hester Biosciences Gets Board Nod to Divest 43.8% Stake in Subsidiary; Shares Up 3% | MT |
| 11/03 | Hester Biosciences approves divestment of 43.81% equity in Texas Lifesciences | RE |
Sales 2025 by Business Segment
Sales 2025 by Geography
Historical Breakdown of Revenue by Business Segments
Operating Income: Breakdown by Business Segment
| Fiscal Period: March | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
Biological Products | ||||||||||
Poultry Healthcare | 156.45Cr | 171.83Cr | 141.32Cr | 145.25Cr | 167.45Cr | |||||
Total Assets | 189.14Cr | 236.08Cr | 242.28Cr | 245.35Cr | 261.44Cr | |||||
CAPEX | -40Cr | -22Cr | -60Cr | -15Cr | -15Cr | |||||
D&A | - | - | - | - | - | |||||
Operating Income | 39Cr | 55Cr | 27Cr | 18Cr | 27Cr | |||||
Animal Healthcare | 58Cr | 63Cr | 114.14Cr | 129.86Cr | 143.65Cr | |||||
Total Assets | 199.36Cr | 212.34Cr | 214.28Cr | 211.99Cr | 194.66Cr | |||||
CAPEX | -73.7L | -17.3L | -11Cr | -1.35Cr | -2.62Cr | |||||
D&A | - | - | - | - | - | |||||
Operating Income | 18Cr | 90.6L | 21Cr | 30Cr | 27Cr | |||||
Animal Care Products | ||||||||||
Petcare | - | - | 1.77Cr | 2.64Cr | - | |||||
Total Assets | - | - | 1.39Cr | 1.92Cr | - | |||||
CAPEX | - | - | -60T | -8L | - | |||||
Operating Income | - | - | -39.9L | -1.51Cr | - | |||||
Veterinary Drugs | ||||||||||
Others | - | - | 8.87Cr | 27Cr | - | |||||
Total Assets | - | - | 11Cr | 27.8L | 28.5L | |||||
CAPEX | - | - | - | - | -5.5Cr | |||||
Operating Income | - | - | 3.44Cr | 6.89Cr | - | |||||
CAPEX | - | - | - | - | - | |||||
D&A | - | - | - | - | - | |||||
Total Assets | - | 113.75Cr | 200.76Cr | 202.8Cr | 197.01Cr | |||||
Operating Income | - | - | - | - | - | |||||
D&A | - | - | - | - | - | |||||
CAPEX | - | - | - | - | - | |||||
Total Assets | - | - | - | - | - |
Geographical Revenue Distribution History
| Fiscal Period: March | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
India | 171.11Cr | 190.18Cr | 216.92Cr | 239.17Cr | 260.95Cr | |||||
Total Assets | 402.1Cr | 399.38Cr | 265.72Cr | 286.02Cr | 299.82Cr | |||||
outside India | 43Cr | 45Cr | 49Cr | 65Cr | 50Cr | |||||
Total Assets | 8.94Cr | 162.78Cr | 142.25Cr | 128Cr | 118.76Cr | |||||
Unallocated | - | - | - | - | - | |||||
Unallocated Sale of Services | - | - | - | - | - | |||||
Unallocated Other Operating Revenue | - | - | - | - | - | |||||
Unallocated Excise Duty | - | - | - | - | - | |||||
Corporate | - | - | - | - | - |
- Stock Market
- Equities
- 524669 Stock
- Financials Hester Biosciences Limited
- Business Segments
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition